

83 Cherry Lane Laverton North, VIC 3026 AUSTRALIA

Phone: + 61 3 9278 7555 Fax: + 61 3 9369 6730

www.probiotec.com.au

ASX ANNOUNCEMENT

14 July 2014

CLINICAL TRIAL COMMENCEMENT

The directors of Probiotec Limited (ASX: PBP) ("the Company") are pleased to announce that further to the ongoing research and development program with Griffith University and other research organisations, the Company has commenced a clinical trial to investigate the effectiveness of Glycomax Lactoferrin ("Lactoferrin") and bovine whey derived Ig rich fraction ("Immunoglobulin") for the treatment of atopic dermatitis. The study will be undertaken in conjunction with Associate Professor Stephen Shumack and Dr Phillip Tong of the St George Dermatology and Skin Cancer Clinic. Concurrently with this trial, the Company is also undertaking a gene expression study utilising Lactoferrin and Immunoglobulin with Griffith University.

The trial aims to examine the effect of speciality milk proteins (being Lactoferrin and Immunoglobulin) on atopic dermatitis, otherwise known as Eczema. Eczema is an inflammatory skin condition that is estimated to affect between 2% to 10% of adults in Australia and is more prevalent in children.

Ethics approval for this trial has been obtained with recruitment now underway. The Company expects the trial to be completed prior to the end of the 2015 financial year.

If successful, this trial would provide a major step forward in the field for the treatment of a condition that currently has no cure.

Further details on the study can be found at the link below: http://app.griffith.edu.au/news/2014/06/12/using-milk-proteins-to-treat-eczema/

A recent new story aired on Channel Nine news can be accessed using the link below: http://video.au.msn.com/watch/video/researchers-investigate-treatments-for-eczema/xttlhuf

Further details on this trial will be advised as and when they become available.

About Probiotec

Probiotec Limited is a brand owner, manufacturer, marketer and distributor of a range of prescription and over-the-counter (OTC) pharmaceuticals, complementary medicines and specialty ingredients. The company owns four manufacturing facilities in Australia and distributes its products both domestically and internationally. Products are manufactured by Probiotec for both its own products and on behalf of others, including major international pharmaceutical companies.

Further details about Probiotec are available at www.probiotec.com.au.

For further information contact:

Mr Wayne Stringer, Managing Director 0412 520 609

About Griffith University

Griffith University does independent clinical research and studies which are based on vigorous, high quality evidence. Griffith University will engage with different partners on various studies from time to time. However it does not endorse any one organisation's products or services as a result of these commercial relationships.